Elza Lomaia

A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

Delphine Réa, Michael J. Mauro, Carla Boquimpani et al. · Blood · 2021 · 336 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +6

Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial

Jörge E. Cortes, Jane F. Apperley, Elza Lomaia et al. · Blood · 2021 · 193 citations · Full text

Medicine, Oncology, Pharmacology +6

Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL

Andreas Hochhaus, Delphine Réa, Carla Boquimpani et al. · Leukemia · 2023 · 135 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

First‐line treatment selection and early monitoring patterns in chronic phase‐chronic myeloid leukemia in routine clinical practice: SIMPLICITY

Stuart L. Goldberg, Jörge E. Cortes, Carlo Gambacorti‐Passerini et al. · American Journal of Hematology · 2017 · 39 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study

Vikas Gupta, Martin Grießhammer, Bruno Martino et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2020 · 36 citations · Full text

Medicine, Hematology, Pharmacology +13